Advanced search
Start date

Mechanism of action of bromocriptine and prolactin antagonists in the treatment of Diabetes and Obesity

Grant number: 13/21722-4
Support Opportunities:Scholarships in Brazil - Doctorate
Effective date (Start): March 01, 2014
Effective date (End): October 31, 2016
Field of knowledge:Biological Sciences - Physiology - Physiology of Organs and Systems
Principal Investigator:Jose Donato Junior
Grantee:Isadora Clivatti Furigo
Host Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil


The type 2 diabetes mellitus (T2DM) is a metabolic disease characterized by dysfunctions in the metabolism of glucose, amino acids and free fat acids. Although most therapies to treat diabetes have peripheral effects, a growing number of studies show that the brain plays a critical role in the control of glucose homeostasis. The quick release bromocriptine mesylate (Cycloset®) was the first FDA approved drug to treat T2DM that has its primary actions on central nervous system. Several studies have shown beneficial effects of bromocriptine, a dopaminergic agonist, to reduce hyperglycemia and hyperlipidemia in obese animals. Therefore, a possible mechanism of action of this drug can be by blocking prolactin secretion. High serum prolactin levels in patients with prolactinomas or during the usage of antipsychotics cause abnormalities in the metabolism of carbohydrates and lipids, resembling the features of the metabolic syndrome. At the present study, we hypothesized that at least part of the beneficial effects of bromocriptine is mediated by inhibiting prolactin secretion. In this context, we believe that administration of prolactin antagonist (anti-PrlR) may be a promising approach for the treatment of diabetes and obesity. Based on this hypothesis, we will carry out experiments in four groups of genetically obese and diabetic mice (ob/ob): 1) control group, 2) group treated with prolactin, 3) group treated with bromocriptine, and 4) group treated with bromocriptine and prolactin. Another group of animals will receive Anti-PrlR and their results will be compared with those observed in control animals and in a group that will be treated with bromocriptine. We will assess whether Anti-PrlR improve the diabetes and obesity phenotype of ob/ob mice. Thus, if we confirm our hypothesis, the anti-PrlR may become a new class of drugs for the treatment of metabolic diseases such as obesity and T2DM.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications (13)
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
FURIGO, ISADORA C.; KIM, KI WOO; NAGAISHI, VANESSA S.; RAMOS-LOBO, ANGELA M.; DE ALENCAR, AMANDA; PEDROSO, JOAO A. B.; METZGER, MARTIN; DONATO, JR., JOSE. Prolactin-sensitive neurons express estrogen receptor-alpha and depend on sex hormones for normal responsiveness to prolactin. Brain Research, v. 1566, p. 47-59, . (13/21722-4, 12/02388-3, 10/18086-0, 13/16374-7)
DA SILVA, EDUARDO SIMAO; FLORES, RAFAEL APPEL; RIBAS, ANDERSON SAVARIS; TASCHETTO, ANA PAULA; FARIA, MOACIR SERRALVO; LIMA, LEANDRO BUENO; METZGER, MARTIN; DONATO, JR., JOSE; PASCHOALINI, MARTA APARECIDA. Injections of the of the alpha(1)-adrenoceptor antagonist prazosin into the median raphe nucleus increase food intake and Fos expression in orexin neurons of free-feeding rats. Behavioural Brain Research, v. 324, p. 87-95, . (12/02388-3, 13/21722-4, 10/18086-0)
DA SILVA, REGINA P.; ZAMPIERI, THAIS T.; PEDROSO, JOAO A. B.; NAGAISHI, VANESSA S.; RAMOS-LOBO, ANGELA M.; FURIGO, ISADORA C.; CAMARA, NIELS O.; FRAZAO, RENATA; DONATO, JR., JOSE. Leptin Resistance Is Not the Primary Cause of Weight Gain Associated With Reduced Sex Hormone Levels in Female Mice. Endocrinology, v. 155, n. 11, p. 4226-4236, . (13/00801-3, 10/18086-0, 12/12202-4, 13/16374-7, 12/02270-2, 12/15517-6, 13/21722-4)
BUONFIGLIO, DANIELLA C.; RAMOS-LOBO, ANGELA M.; SILVEIRA, MARINA A.; FURIGO, ISADORA C.; HENNIGHAUSEN, LOTHAR; FRAZAO, RENATA; DONATO, JR., JOSE. Neuronal STAT5 signaling is required for maintaining lactation but not for postpartum maternal behaviors in mice. Hormones and Behavior, v. 71, p. 60-68, . (12/12202-4, 13/21722-4, 14/11752-6)
LIMA, LEANDRO B.; BUENO, DEBORA; LEITE, FERNANDA; SOUZA, STEFANI; GONCALVES, LUCIANO; FURIGO, ISADORA C.; DONATO, JR., JOSE; METZGER, MARTIN. Afferent and efferent connections of the interpeduncular nucleus with special reference to circuits involving the habenula and raphe nuclei. JOURNAL OF COMPARATIVE NEUROLOGY, v. 525, n. 10, p. 2411-2442, . (13/21722-4, 10/18086-0, 12/02388-3)
SILVEIRA, MARINA AUGUSTO; FURIGO, ISADORA C.; ZAMPIERI, THAIS T.; BOHLEN, TABATA M.; DE PAULA, DANIELLA G.; FRANCI, CELSO RODRIGUES; DONATO, JR., JOSE; FRAZAO, RENATA. STAT5 signaling in kisspeptin cells regulates the timing of puberty. Molecular and Cellular Endocrinology, v. 448, n. C, p. 55-65, . (15/20198-5, 12/12202-4, 15/10992-6, 13/07908-8, 13/21722-4, 15/14588-5)
PEDROSO, JOAO A. B.; BUONFIGLIO, DANIELLA C.; CARDINALI, LAIS I.; FURIGO, ISADORA C.; RAMOS-LOBO, ANGELA M.; TIRAPEGUI, JULIO; ELIAS, CAROL F.; DONATO, JR., JOSE. Inactivation of SOCS3 in leptin receptor-expressing cells protects mice from diet-induced insulin resistance but does not prevent obesity. MOLECULAR METABOLISM, v. 3, n. 6, p. 608-618, . (10/18086-0, 13/21722-4)
PEDROSO, JOAO A. B.; DE MENDONCA, PEDRO O. R.; FORTES, MARCO A. S.; TOMAZ, IGOR; PECORALI, VITOR L.; AURICINO, THAIS B.; COSTA, ISMAEL C.; LIMA, LEANDRO B.; FURIGO, ISADORA C.; BUENO, DEBORA N.; et al. SOCS3 expression in SF1 cells regulates adrenal differentiation and exercise performance. Journal of Endocrinology, v. 235, n. 3, p. 207-222, . (10/18086-0, 12/23535-4, 13/21722-4, 14/11752-6, 14/50140-6, 15/10992-6)
FURIGO, ISADORA C.; SUZUKI, MIRIAM F.; OLIVEIRA, JOAO E.; RAMOS-LOBO, ANGELA M.; TEIXEIRA, PRYSCILA D. S.; PEDROSO, JOAO A.; DE ALENCAR, AMANDA; ZAMPIERI, THAIS T.; BUONFIGLIO, DANIELLA C.; QUARESMA, PAULA G. F.; et al. Suppression of Prolactin Secretion Partially Explains the Antidiabetic Effect of Bromocriptine in ob/ob Mice. Endocrinology, v. 160, n. 1, p. 193-204, . (13/25032-2, 14/11752-6, 15/10992-6, 12/15517-6, 13/21722-4, 17/25281-3, 12/24345-4)
PEDROSO, JOAO A. B.; SILVEIRA, MARINA A.; LIMA, LEANDRO B.; FURIGO, ISADORA C.; ZAMPIERI, THAIS T.; RAMOS-LOBO, ANGELA M.; BUONFIGLIO, DANIELLA C.; TEIXEIRA, PRYSCILA D. S.; FRAZAO, RENATA; DONATO, JR., JOSE. Changes in Leptin Signaling by SOCS3 Modulate Fasting-Induced Hyperphagia and Weight Regain in Mice. Endocrinology, v. 157, n. 10, p. 3901-3914, . (13/25032-2, 10/18086-0, 14/11752-6, 12/12202-4, 15/10992-6, 13/07908-8, 12/15517-6, 13/21722-4)
FURIGO, ISADORA C.; METZGER, MARTIN; TEIXEIRA, PRYSCILA D. S.; SOARES, CARLOS R. J.; DONATO, JR., JOSE. Distribution of growth hormone-responsive cells in the mouse brain. Brain Structure & Function, v. 222, n. 1, p. 341-363, . (12/24345-4, 10/18086-0, 13/21722-4, 12/02388-3)
FURIGO, ISADORA C.; RAMOS-LOBO, ANGELA M.; FRAZAO, RENATA; DONATO, JR., J.. Brain STAT5 signaling and behavioral control. Molecular and Cellular Endocrinology, v. 438, n. C, p. 70-76, . (14/11752-6, 12/12202-4, 10/18086-0, 15/10992-6, 13/07908-8, 13/21722-4)
Academic Publications
(References retrieved automatically from State of São Paulo Research Institutions)
FURIGO, Isadora Clivatti. The study of the mechanisms of action of bromocriptine and prolactin antagonists to treat Type 2 Diabetes Mellitus and Obesity.. 2016. Doctoral Thesis - Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB/SDI) São Paulo.

Please report errors in scientific publications list by writing to: